Loading…
Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma
To analyze the contrast-enhanced ultrasound (CEUS) manifestations of combined hepatocellular-cholangiocarcinoma (CHC) and to investigate the diagnostic value of the 2017 version of the CEUS Liver Imaging Reporting and Data System (LI-RADS) and serum tumor markers in CHC. A total of 66 pathologically...
Saved in:
Published in: | European journal of radiology 2022-09, Vol.154, p.110415-110415, Article 110415 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3 |
container_end_page | 110415 |
container_issue | |
container_start_page | 110415 |
container_title | European journal of radiology |
container_volume | 154 |
creator | Wen, Rong Lin, Peng Wu, Yuquan Yin, Haihui Huang, Weiche Guo, Danxia Peng, Yuye Liu, Dun He, Yun Yang, Hong |
description | To analyze the contrast-enhanced ultrasound (CEUS) manifestations of combined hepatocellular-cholangiocarcinoma (CHC) and to investigate the diagnostic value of the 2017 version of the CEUS Liver Imaging Reporting and Data System (LI-RADS) and serum tumor markers in CHC.
A total of 66 pathologically confirmed CHC nodules were retrospectively analyzed. We summarized the CEUS manifestations of CHC and analyzed the relationship between serum tumor markers and the enhancement pattern of CHC. We also classified CHC according to CEUS LI-RADS criteria. The Kappa test was used to assess the interreader agreement of CEUS LI-RADS between radiologists.
According to the results, 52 of 62 (83.9%) patients had elevated alpha-fetoprotein (AFP), 19 of 61 (31.1%) had elevated carbohydrate antigen 199 (CA 199), and 13 of 61 (21.3%) had both elevated AFP and CA 199. Of the 66 CHC nodules, 64 (97.0%) were identified as malignant lesions by CEUS, 13 (19.7%) showed a hepatocellular carcinoma-like enhancement pattern, and 21 (31.8%) showed a cholangiocarcinoma-like enhancement pattern. For the CEUS LI-RADS categories, 39 of 53 (73.6%) CHC nodules were classified as LR-M, 12 (22.6%) were classified as LR-5, and 2 (3.8%) were classified as LR-4. The interreader agreement for the LI-RADS categories was 0.60.
Although CHC lacks specific CEUS features, CEUS LI-RADS and serum tumor markers can be useful tools for reducing the misdiagnosis of CHC. In addition, due to the relative complexity of the CEUS features involved in CHC, it is necessary for beginning radiologists to learn more about CEUS features. |
doi_str_mv | 10.1016/j.ejrad.2022.110415 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2681048776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0720048X22002650</els_id><sourcerecordid>2681048776</sourcerecordid><originalsourceid>FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EEqXwC1g8sqTYbhK7A0PV8lGpEhKlEptlO-fWIYmLnVTi35MSZqa74X1O9z4I3VIyoYTm9-UEyqCKCSOMTSglKc3O0IgKzhLOGT9HI8IZSUgqPi7RVYwlISRLZ2yEdkundo2PrTP4qKoOsLd48bjd4PUqeZsvN1g1BY4Quhq3Xe0DrlX4hBCx7Xfja-0aKPAeDqr1Bqqqq1RIzN5Xqtk5b1QwrvG1ukYXVlURbv7mGG2fHt8XL8n69Xm1mK8Tw_K8TSxnVAtqdVaYLJ-JKQGiBAjFuNF9Kys0ESrnmhUzbnVBtBHaphnlgmuTwnSM7oa7h-C_OoitrF08_aUa8F2ULBe9HsF53kenQ9QEH2MAKw_B9e2-JSXypFWW8lerPGmVg9aeehgo6FscHQQZjYPGQOECmFYW3v3L_wDMRoKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2681048776</pqid></control><display><type>article</type><title>Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Wen, Rong ; Lin, Peng ; Wu, Yuquan ; Yin, Haihui ; Huang, Weiche ; Guo, Danxia ; Peng, Yuye ; Liu, Dun ; He, Yun ; Yang, Hong</creator><creatorcontrib>Wen, Rong ; Lin, Peng ; Wu, Yuquan ; Yin, Haihui ; Huang, Weiche ; Guo, Danxia ; Peng, Yuye ; Liu, Dun ; He, Yun ; Yang, Hong</creatorcontrib><description>To analyze the contrast-enhanced ultrasound (CEUS) manifestations of combined hepatocellular-cholangiocarcinoma (CHC) and to investigate the diagnostic value of the 2017 version of the CEUS Liver Imaging Reporting and Data System (LI-RADS) and serum tumor markers in CHC.
A total of 66 pathologically confirmed CHC nodules were retrospectively analyzed. We summarized the CEUS manifestations of CHC and analyzed the relationship between serum tumor markers and the enhancement pattern of CHC. We also classified CHC according to CEUS LI-RADS criteria. The Kappa test was used to assess the interreader agreement of CEUS LI-RADS between radiologists.
According to the results, 52 of 62 (83.9%) patients had elevated alpha-fetoprotein (AFP), 19 of 61 (31.1%) had elevated carbohydrate antigen 199 (CA 199), and 13 of 61 (21.3%) had both elevated AFP and CA 199. Of the 66 CHC nodules, 64 (97.0%) were identified as malignant lesions by CEUS, 13 (19.7%) showed a hepatocellular carcinoma-like enhancement pattern, and 21 (31.8%) showed a cholangiocarcinoma-like enhancement pattern. For the CEUS LI-RADS categories, 39 of 53 (73.6%) CHC nodules were classified as LR-M, 12 (22.6%) were classified as LR-5, and 2 (3.8%) were classified as LR-4. The interreader agreement for the LI-RADS categories was 0.60.
Although CHC lacks specific CEUS features, CEUS LI-RADS and serum tumor markers can be useful tools for reducing the misdiagnosis of CHC. In addition, due to the relative complexity of the CEUS features involved in CHC, it is necessary for beginning radiologists to learn more about CEUS features.</description><identifier>ISSN: 0720-048X</identifier><identifier>EISSN: 1872-7727</identifier><identifier>DOI: 10.1016/j.ejrad.2022.110415</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Alpha-fetoprotein ; Carbohydrate antigen 199 ; Combined hepatocellular-cholangiocarcinoma ; Contrast-enhanced ultrasound ; Liver Imaging Reporting and Data System</subject><ispartof>European journal of radiology, 2022-09, Vol.154, p.110415-110415, Article 110415</ispartof><rights>2022 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3</citedby><cites>FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Wen, Rong</creatorcontrib><creatorcontrib>Lin, Peng</creatorcontrib><creatorcontrib>Wu, Yuquan</creatorcontrib><creatorcontrib>Yin, Haihui</creatorcontrib><creatorcontrib>Huang, Weiche</creatorcontrib><creatorcontrib>Guo, Danxia</creatorcontrib><creatorcontrib>Peng, Yuye</creatorcontrib><creatorcontrib>Liu, Dun</creatorcontrib><creatorcontrib>He, Yun</creatorcontrib><creatorcontrib>Yang, Hong</creatorcontrib><title>Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma</title><title>European journal of radiology</title><description>To analyze the contrast-enhanced ultrasound (CEUS) manifestations of combined hepatocellular-cholangiocarcinoma (CHC) and to investigate the diagnostic value of the 2017 version of the CEUS Liver Imaging Reporting and Data System (LI-RADS) and serum tumor markers in CHC.
A total of 66 pathologically confirmed CHC nodules were retrospectively analyzed. We summarized the CEUS manifestations of CHC and analyzed the relationship between serum tumor markers and the enhancement pattern of CHC. We also classified CHC according to CEUS LI-RADS criteria. The Kappa test was used to assess the interreader agreement of CEUS LI-RADS between radiologists.
According to the results, 52 of 62 (83.9%) patients had elevated alpha-fetoprotein (AFP), 19 of 61 (31.1%) had elevated carbohydrate antigen 199 (CA 199), and 13 of 61 (21.3%) had both elevated AFP and CA 199. Of the 66 CHC nodules, 64 (97.0%) were identified as malignant lesions by CEUS, 13 (19.7%) showed a hepatocellular carcinoma-like enhancement pattern, and 21 (31.8%) showed a cholangiocarcinoma-like enhancement pattern. For the CEUS LI-RADS categories, 39 of 53 (73.6%) CHC nodules were classified as LR-M, 12 (22.6%) were classified as LR-5, and 2 (3.8%) were classified as LR-4. The interreader agreement for the LI-RADS categories was 0.60.
Although CHC lacks specific CEUS features, CEUS LI-RADS and serum tumor markers can be useful tools for reducing the misdiagnosis of CHC. In addition, due to the relative complexity of the CEUS features involved in CHC, it is necessary for beginning radiologists to learn more about CEUS features.</description><subject>Alpha-fetoprotein</subject><subject>Carbohydrate antigen 199</subject><subject>Combined hepatocellular-cholangiocarcinoma</subject><subject>Contrast-enhanced ultrasound</subject><subject>Liver Imaging Reporting and Data System</subject><issn>0720-048X</issn><issn>1872-7727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAQhi0EEqXwC1g8sqTYbhK7A0PV8lGpEhKlEptlO-fWIYmLnVTi35MSZqa74X1O9z4I3VIyoYTm9-UEyqCKCSOMTSglKc3O0IgKzhLOGT9HI8IZSUgqPi7RVYwlISRLZ2yEdkundo2PrTP4qKoOsLd48bjd4PUqeZsvN1g1BY4Quhq3Xe0DrlX4hBCx7Xfja-0aKPAeDqr1Bqqqq1RIzN5Xqtk5b1QwrvG1ukYXVlURbv7mGG2fHt8XL8n69Xm1mK8Tw_K8TSxnVAtqdVaYLJ-JKQGiBAjFuNF9Kys0ESrnmhUzbnVBtBHaphnlgmuTwnSM7oa7h-C_OoitrF08_aUa8F2ULBe9HsF53kenQ9QEH2MAKw_B9e2-JSXypFWW8lerPGmVg9aeehgo6FscHQQZjYPGQOECmFYW3v3L_wDMRoKw</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Wen, Rong</creator><creator>Lin, Peng</creator><creator>Wu, Yuquan</creator><creator>Yin, Haihui</creator><creator>Huang, Weiche</creator><creator>Guo, Danxia</creator><creator>Peng, Yuye</creator><creator>Liu, Dun</creator><creator>He, Yun</creator><creator>Yang, Hong</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202209</creationdate><title>Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma</title><author>Wen, Rong ; Lin, Peng ; Wu, Yuquan ; Yin, Haihui ; Huang, Weiche ; Guo, Danxia ; Peng, Yuye ; Liu, Dun ; He, Yun ; Yang, Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alpha-fetoprotein</topic><topic>Carbohydrate antigen 199</topic><topic>Combined hepatocellular-cholangiocarcinoma</topic><topic>Contrast-enhanced ultrasound</topic><topic>Liver Imaging Reporting and Data System</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wen, Rong</creatorcontrib><creatorcontrib>Lin, Peng</creatorcontrib><creatorcontrib>Wu, Yuquan</creatorcontrib><creatorcontrib>Yin, Haihui</creatorcontrib><creatorcontrib>Huang, Weiche</creatorcontrib><creatorcontrib>Guo, Danxia</creatorcontrib><creatorcontrib>Peng, Yuye</creatorcontrib><creatorcontrib>Liu, Dun</creatorcontrib><creatorcontrib>He, Yun</creatorcontrib><creatorcontrib>Yang, Hong</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wen, Rong</au><au>Lin, Peng</au><au>Wu, Yuquan</au><au>Yin, Haihui</au><au>Huang, Weiche</au><au>Guo, Danxia</au><au>Peng, Yuye</au><au>Liu, Dun</au><au>He, Yun</au><au>Yang, Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma</atitle><jtitle>European journal of radiology</jtitle><date>2022-09</date><risdate>2022</risdate><volume>154</volume><spage>110415</spage><epage>110415</epage><pages>110415-110415</pages><artnum>110415</artnum><issn>0720-048X</issn><eissn>1872-7727</eissn><abstract>To analyze the contrast-enhanced ultrasound (CEUS) manifestations of combined hepatocellular-cholangiocarcinoma (CHC) and to investigate the diagnostic value of the 2017 version of the CEUS Liver Imaging Reporting and Data System (LI-RADS) and serum tumor markers in CHC.
A total of 66 pathologically confirmed CHC nodules were retrospectively analyzed. We summarized the CEUS manifestations of CHC and analyzed the relationship between serum tumor markers and the enhancement pattern of CHC. We also classified CHC according to CEUS LI-RADS criteria. The Kappa test was used to assess the interreader agreement of CEUS LI-RADS between radiologists.
According to the results, 52 of 62 (83.9%) patients had elevated alpha-fetoprotein (AFP), 19 of 61 (31.1%) had elevated carbohydrate antigen 199 (CA 199), and 13 of 61 (21.3%) had both elevated AFP and CA 199. Of the 66 CHC nodules, 64 (97.0%) were identified as malignant lesions by CEUS, 13 (19.7%) showed a hepatocellular carcinoma-like enhancement pattern, and 21 (31.8%) showed a cholangiocarcinoma-like enhancement pattern. For the CEUS LI-RADS categories, 39 of 53 (73.6%) CHC nodules were classified as LR-M, 12 (22.6%) were classified as LR-5, and 2 (3.8%) were classified as LR-4. The interreader agreement for the LI-RADS categories was 0.60.
Although CHC lacks specific CEUS features, CEUS LI-RADS and serum tumor markers can be useful tools for reducing the misdiagnosis of CHC. In addition, due to the relative complexity of the CEUS features involved in CHC, it is necessary for beginning radiologists to learn more about CEUS features.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.ejrad.2022.110415</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0720-048X |
ispartof | European journal of radiology, 2022-09, Vol.154, p.110415-110415, Article 110415 |
issn | 0720-048X 1872-7727 |
language | eng |
recordid | cdi_proquest_miscellaneous_2681048776 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Alpha-fetoprotein Carbohydrate antigen 199 Combined hepatocellular-cholangiocarcinoma Contrast-enhanced ultrasound Liver Imaging Reporting and Data System |
title | Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A33%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20value%20of%20CEUS%20LI-RADS%20and%20serum%20tumor%20markers%20for%20combined%20hepatocellular-cholangiocarcinoma&rft.jtitle=European%20journal%20of%20radiology&rft.au=Wen,%20Rong&rft.date=2022-09&rft.volume=154&rft.spage=110415&rft.epage=110415&rft.pages=110415-110415&rft.artnum=110415&rft.issn=0720-048X&rft.eissn=1872-7727&rft_id=info:doi/10.1016/j.ejrad.2022.110415&rft_dat=%3Cproquest_cross%3E2681048776%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c266t-f721b81fb5dc569830e0a8e8a27cb415f8b08a67b2d97fbd0bc8bf451787bc4e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2681048776&rft_id=info:pmid/&rfr_iscdi=true |